



25 November 2024



PolyNovo Limited ABN 96 083 866 862

2/320 Lorimer Street Port Melbourne VIC Australia 3207

P +61 (0) 3 8681 4050 F +61 (0) 3 8681 4099

## **ASX Announcement**

## **Bell Potter Healthcare Conference Recording**

The interview of David Williams, PolyNovo Limited Chairman, by Bell Potter healthcare analyst John Hester at the Bell Potter Healthcare Conference on 18 November 2024 can be viewed via the following link:

https://www.youtube.com/watch?v=n7kwhOMlPbI

This announcement has been authorised by PolyNovo Board.

## **About PolyNovo®**

PolyNovo is a disruptive ASX 200 medical technology company, based out of Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 50,000+ patients across 42 countries, the company is investing for growth via new products, indications, and markets. For more information see polynovo.com

## About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.